Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 2 Clinical Study to Evaluate the Safety and Efficacy of PA9159 Nasal Spray for the Treatment of Seasonal Allergic Rhinitis
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to evaluate the safety, efficacy and characteristics of population pharmacokinetics of multiple dosing of PA9159 Nasal Spray in patients with seasonal allergic rhinitis.
评价 PA9159 鼻喷雾剂在季节性过敏性鼻炎受试者中的安全性及有效性的Ⅱ期临床研究
[Translation] Phase II clinical study to evaluate the safety and efficacy of PA9159 nasal spray in subjects with seasonal allergic rhinitis
主要目的:评价 PA9159 鼻喷雾剂在季节性过敏性鼻炎患者中多次鼻喷给药的有效性。
次要目的:评价 PA9159 鼻喷雾剂在季节性过敏性鼻炎患者中多次鼻喷给药的安全性和群体药代动力学特征。
[Translation] Primary objective: To evaluate the efficacy of multiple nasal spray administration of PA9159 nasal spray in patients with seasonal allergic rhinitis.
Secondary objective: To evaluate the safety and population pharmacokinetics of PA9159 nasal spray in patients with seasonal allergic rhinitis after multiple nasal spray administration.
A Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics of Single Dose and 7-day Repeat Doses of PA9159 Nasal Spray in Healthy Chinese Adult
PA9159 is a highly potent novel corticosteroid. The purpose of this study is to exam the safety, tolerability, and pharmacokinetics of single and repeat dosing of intranasal PA9159, to establish maximum tolerated dose in healthy chinese adult
100 Clinical Results associated with Anhui Palo Alto Pharmaceutials Inc
0 Patents (Medical) associated with Anhui Palo Alto Pharmaceutials Inc
100 Deals associated with Anhui Palo Alto Pharmaceutials Inc
100 Translational Medicine associated with Anhui Palo Alto Pharmaceutials Inc